Volume : 10, Issue : 02, February – 2023
Title:
09.FORMULATION AND OPTIMIZATION OF MOUTH DISSOLVING TABLET CONTAINING INDOMETHACIN SOLID DISPERSION
Authors :
Chinnam Surekha, Zeenath Ruhy
Abstract :
Indomethacin is a non-steroidal anti-inflammatory drug mainly used for musculo skeletal & joint disorders including ankylosing, spondilitis, osteoarthritis, rhematiod arthiritis acute gout & in inflammation and pain. The major drawback of this drug is its very low water solubility and low erratic absorption from GIT. The purpose of the present investigation was to increase the solubility and dissolution rate of Indomethacin by the preparation of its solid dispersion with polyvinyl pyrrolidone k30, PEG-4000and PEG-6000 using solvent evaporation and physical mixture method and preparation of MDT of indomethacin with different superdisintegrant and sublimable material.Drug polymer interaction were investigated (XRD) and (FTIR). The DSC, XRD and FTIR results showed no drug-polymer chemical interaction in the solid dispersion. Indomethacin solid dispersion with PVP K-30 (1:5) by solvent evaporation was used for the preparation of mouth dissolving tablet with various superdisintegrant by direct compression and sublimation method. The formulated fast dissolving tablets were evaluated for hardness, friability, wetting time, disintegration and in vitro drug released. The hardness of the prepared tablets were found in the range of 2.4 kg/cm2 to 3.2 kg/cm2. The friability values were less than 1%. All the formulation had disintegration time less than 1 min. The formulation SBP3 containing 4% crosspovidone showed 99.93% drug released within 5 min. FT-IR spectra revealed no chemical incompatibility between the drug and PVP K-30. The stability studies were conducted as per ICH guidelines and the formulations were found to be stable with insignificant change in the hardness, disintegration and in vitro drug released pattern.
KEYWORDS: Indomethacin; Solid dispersion, polyvinyl pyrrolidone K-30; mouth dissolving tablet; superdisintigrants.
Cite This Article:
Please cite this article in press Chinnam Surekha et al, Formulation And Optimization Of Mouth Dissolving Tablet Containing Indomethacin Solid Dispersion., Indo Am. J. P. Sci, 2023; 10 (02).
Number of Downloads : 10
References:
2. Bandari S. Orodispersible tablets An Overview, Asian J. Pharm.2008; 1: 2-11.
3. Panigrahi D, Baghel S, and Mishra B. Mouth dissolving tablets:an overview of preparation techniques, evaluation and patentedtechnologies. J. Pharm. Res. 2004; 4(3):33–38.
4. Ghosh T.K. “Orally Disintegrating Tablets,” AAPSNewsmagazine, 2004, 7 (6), 19-21.
5. Pather S.I., Khankari R., and Siebert J,”Quick-DissolvingIntraoral Tablets,” in Drug Delivery to the Oral Cavity:Molecules to Market Ghosh T.K. and Pfister W.R., Eds. (CRCPress, New York, NY, 2005), pp. 291–336.
6. Stetsko G. Statistical experimental design and its application to pharmaceutical development problems. Drug Dev Ind. Pharm. 1986; 12:1109-1123.
7. Gohel M, Formulation design and optimization of mouth dissolve tablets of nimesulide using vacuum drying technique. AAPS PharmSciTech. 2004; 5:E36.
8. Omaima A. Sammour, Formulation and Optimization of Mouth Dissolve Tablets Containing Rofecoxib Solid Dispersion. AAPS PharmSciTech 2006; 7 (2) Article 55 .
9. Zaghloul A, Faltinek J, Reddy IK, Khan MA. Response surface methodology to obtain naproxen controlled release tablets from its microspheres with Eudragit L 100-55. J Micro-encapsul. 2001; 18(5):651-662.
10. Lucas S: The Pharmacology of Indomethacin. Headache. 2016 Feb;56(2):436-46. doi: 10.1111/head.12769. Epub 2016 Feb 11. [Article]
11. Helleberg L: Clinical Pharmacokinetics of indomethacin. Clin Pharmacokinet. 1981 Jul-Aug;6(4):245-58. doi: 10.2165/00003088-198106040-00001. [Article]
12. Nalamachu S, Wortmann R: Role of indomethacin in acute pain and inflammation management: a review of the literature. Postgrad Med. 2014 Jul;126(4):92-7. doi: 10.3810/pgm.2014.07.2787. [Article]
13. Pacifici GM: Clinical pharmacology of indomethacin in preterm infants: implications in patent ductus arteriosus closure. Paediatr Drugs. 2013 Oct;15(5):363-76. doi: 10.1007/s40272-013-0031-7. [Article]